

# **Erythromycin Ophthalmic Ointment, 0.5%**

#### **Section 1 - IDENTIFICATION**

**Product Identifier:** Erythromycin Ophthalmic Ointment, USP 0.5%

**Synonyms:** Erythromycin Base; (3R\*, 4S\*, 5S\*, 6R\*, 7R\*, 9R\*,11R\*, 12R\*, 13S\*, 14R\*)-4-[(2,6-dideoxy-

3-C-methyl-3- Omethyl-α-L-ribo-hexopyranosyl)-oxy]-14-ethyl-7,12,13- trihydroxy-

3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3- (dimethyl-amino)-D-xylo-

hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione.

**NDC Code:** 72485-670-35 3.5 g

72485-670-31 1 g

**Recommended Use:** Pharmaceutical

Manufacturer: Ophtapharm AG

Riethofstrasse 1 CH-8442 Hettlingen

Switzerland

**Telephone:** +1855-473-6847 **Email:** quality@sentiss.ch

## Section 2 – HAZARD(S) IDENTIFICATION

Physical Hazards:Not classifiable.Health Hazards:Not classifiable.Symbol(s):Not classifiable.

Signal Word:

Hazard Statement(s):

Precautionary Statement(s):

None.

None.

Hazards Not Otherwise Classified: Not classifiable.

**Supplementary Information:** While this material is not classifiable as hazardous under the

OSHA standard, this SDS contains valuable information critical to safe handling and proper use of the product. This SDS should be retained and available for employees and

other users of this product.

### Section 3 – COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS Number	Synonyms	Chemical Formula	Molecular Weight	Percentage
Petrolatum (Fonoline)	8009-03- 8	White Petrolatum; Petroleum Jelly; Mineral Grease	No data available.	No data available.	<86%
Mineral Oil (Kaydol)	8042-47- 5	Mineral oil	No data available.	No data available.	<15%

Page 1 of 8 Rev. 00/2023



# **Erythromycin Ophthalmic Ointment, 0.5%**

Erythromycin	114-07-8	Erythromycin Base; (3R*, 4S*, 5S*, 6R*,	C <sub>37</sub> H <sub>67</sub> NO <sub>13</sub>	733.94	0.5 %
		7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-			
		[(2,6-dideoxy-3-C-methyl-3-Omethyl-α-L-			
		ribo-hexopyranosyl)-oxy]-14-ethyl-			
		7,12,13-trihydroxy-3,5,7,9,11,13-			
		hexamethyl-6-[[3,4,6-trideoxy-3-			
		(dimethyl-amino)-D-xylo-			
		hexopyranosyl]oxy]			
		oxacyclotetradecane-2,10-dione.			

### Section 4 – FIRST AID MEASURES

If a person vomits place them in the recovery position so that vomit will not reenter the mouth and throat. Rinse mouth with water. If swallowed, seek medical advice immediately and show the container or label. Treat symptomatically and supportively. Ensure that medical personnel are aware of the material(s) involved and

take precautions to protect themselves.

**Eye Contact:** Remove from source of exposure. Flush with copious amounts of

water for at least 15 minutes. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. Ensure that medical personnel are aware of the material(s) involved and are aware of precautions to protect

themselves.

**Skin Contact:** Remove from source of exposure. Remove and isolate

contaminated clothing and shoes. Flush with copious amounts of water for at least 20 minutes. Use soap. If irritation persists or signs

of toxicity occur, seek medical attention. Provide

symptomatic/supportive care as necessary. Ensure that medical personnel are aware of the material(s) involved and are aware of

precautions to protect themselves.

**Inhalation:** Remove from source of exposure. Move individual(s) to fresh air.

Give artificial respiration if individual(s) are not breathing and call emergency medical service. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. Ensure that medical personnel are aware of the material(s) involved.

and are aware of precautions to protect themselves.

**Protection of First-Aiders:** Use personal protective equipment (see section 8).

Signs and Symptoms: Individuals sensitive to erythromycin or other materials in its chemical

class may develop allergic reactions. Serios allergic reactions, including anaphylaxis, have been reported. If an allergic reaction occurs, the worker should be removed to the nearest emergency room and the appropriate therapy instituted; liver effects, effects on hearing, skin rash; gastrointestinal disturbances (vomiting, abdominal pain, diarrhea,

anorexia, nausea); unusual tiredness or weakness; yellow eyes or skin; sore mouth or tongue; white patches in mouth or on tongue; irregular

Page 2 of 8 Rev. 00/2023



# **Erythromycin Ophthalmic Ointment, 0.5%**

heartbeat.

**Medical Conditions Aggravated** 

by Exposure:

Hypersensitivity to any of the components of the product; impaired

liver function; myasthenia gravis; porphyria; cardiovascular

problems.

**Notes to Physician:** Treat supportively and symptomatically.

**Section 5 – FIREFIGTING MEASURES** 

**Suitable Extinguishing Media:** Use extinguishing media for type of surrounding fire.

Unsuitable Extinguishing Media: Not determined.

Specific Hazards Arising from the Chemical:

Hazardous Combustion These products include carbon oxides, nitrogen oxides and toxic fumes.

**Products:** 

Other Specific Hazards: Closed containers may explode from the heat of fire.

**Special Protective** 

**Equipment/ Precautions for** 

Firefighters:

Wear self-contained breathing apparatus and full and protective gear

Page 3 of 8 Rev. 00/2023



# **Erythromycin Ophthalmic Ointment, 0.5%**

#### **Section 6 – ACCIDENTIAL RELEASE MEASURES**

**Personal Precautions:** Keep unnecessary personnel away. Do not touch damaged containers or

spilled material unless wearing appropriate personal protective equipment a

clothing.

**Personal Protective Equipment:** For personal protection see section 8.

Methods for Cleaning Up: Dike ahead of liquid spills for later disposal. Absorb with inert material. Reco

product and place in an appropriate container for disposal in accordance witl

local, state and federal regulations.

**Environmental Precautions:** Contain material and prevent release to basements, confined spaces,

waterways or soil.

**Reference to Other Sections:** Refer to Sections 8, 12 and 13 for further information.

#### Section 7 – HANDLING AND STORAGE

Precautions for Safe Handling: Handle in accordance with product label and/or product insert

information. Handle in accordance with good industrial hygiene and

safety practices.

Conditions for Safe Storage,

**Including Any Incompatibilities:** Store according to label and/or product insert information. Store away

from oxidizing agents and acids. Store at 20° to 25°C (68° to 77°F).

Specific End Use: Pharmaceutical.

## Section 8 – EXPOSURE CONTROLS/PERSONAL PROTECTION

#### **Occupational Exposure Guidelines:**

Common or Chemical Name	Employee Exposure Limits	
White petrolatum, USP	Not established.	
Mineral Oil	OSHA PEL: 5 mg/m <sup>3</sup> (Mist)	
Erythromycin Base	OEL*: 0.1 mg/m <sup>3</sup> , 8 Hour ;	
	OEL*: 3 mg/m³, 8 Hour	
	A; OEL*: 3 mg/m³, 12 Hour TWA; AIHA WEEL: 3 mg/m³, 8 Hour TWA.	
	AIHA WEEL: 3 mg/m <sup>3</sup> , 8 Hour TWA.	

<sup>\*</sup> Occupational Exposure Levels (OELs) have been established by private industry.

**Engineering Controls:** Engineering controls should be used as the primary means to

control exposures.

**Respiratory Protection:** Where respirators are deemed necessary to reduce or control

occupational exposures, use NIOSH-approved respiratory protection and have an effective respirator program in place (applicable U.S.

regulation OSHA 29 CFR 1910.134).

Page 4 of 8 Rev. 00/2023



## **Erythromycin Ophthalmic Ointment, 0.5%**

**Eyes Protection:** Not required for the normal use of this product. Safety glasses with

side shields are recommended. Face shields or goggles may be required if splash potential exists or if corrosive materials are present. Approved eye protection (e.g., bearing the ANSI Z87 or CSA stamp)

is preferred. Maintain eyewash facilities in the work area.

Hand Protection: Not required for the normal use of this product. Chemically compatible

gloves. For handling solutions, ensure that the glove material is protective against the solvent being used. Use handling practices that minimize direct hand contact. Employees who are sensitive to natural rubber (latex) should use nitrile or other synthetic non-latex gloves. Use of powdered

latex gloves should be avoided due to the risk of latex allergy.

**Skin Protection:** Not required for the normal use of this product. Wear protective

laboratory coat, apron, or disposable garment when working with large

quantities.

#### Section 9 – PHYSICAL AND CHEMICAL PROPERTTIES

Physical State/Color: Semi-solid/colorless to light yellowish translucent.

Odor: No data available. **Odor Threshold:** No data available. No data available. :Ha **Melting Point:** No data available. Freezing Point: No data available. **Boiling Point:** No data available. Flash Point: No data available. **Evaporation Rate:** No data available. Flammability (solid, gas): No data available. Flammability Limit - Lower: No data available. Flammability Limit - Upper: No data available. **Vapor Pressure:** No data available. Vapor Density: No data available. **Relative Density:** No data available.

**Partition Coefficient** 

Solubility(ies):

(n-octanol/water):No data available.Auto-Ignition Temperature:No data available.Decomposition Temperature:No data available.Viscosity:No data available.

# Section 10 – STABILITY AND REACTIVITY

**Reactivity:** No data available.

**Chemical Stability:** Stable under recommended storage conditions.

Possibility of Hazardous Reactions: No data available.

Page 5 of 8 Rev. 00/2023

Immiscible in water.



# **Erythromycin Ophthalmic Ointment, 0.5%**

Conditions to Avoid (e.g., static

discharge, shock, or vibration): No data available.

**Incompatible Materials:** Oxidizing agents, acids and bases.

**Hazardous Decomposition** 

**Products:** No data available.

### Section 11 – TOXICOLOGICAL INFORMATION

#### <u>Information on the Likely Routes of Exposure:</u>

**Inhalation:** May be harmful if inhaled. May cause respiratory tract irritation.

**Ingestion:** May be harmful if swallowed.

**Skin Contact:** May be harmful if absorbed through skin. May cause skin irritation.

**Eye Contact:** May cause eye irritation.

Symptoms Related to the Physical,

**Chemical and Toxicological** 

**Characteristics:** See Section 4. To the best of our knowledge, the chemical, physical

and toxicological properties have not been thoroughly investigated.

**Delayed and Immediate Effects of** 

**Exposure:** No data available.

#### **Acute Toxicity:**

Compound	Species	Test Type	Dose
Petrolatum	Rat	LD <sub>50</sub>	>5,000 mg/kg
Mineral Oil	Rat	LD <sub>50</sub>	>5,000 mg/kg
Erythromycin	Rat	LD <sub>50</sub>	4,600 mg/kg

Acute Toxicity – Dermal:No data available.Acute Toxicity – Inhalation:No data available.Corrosivity:No data available.Dermal Irritation:No data available.Eye Irritation:No data available.

**Sensitization:** Prolonged or repeated exposure (via ingestion,

inhalation or skin contact) may cause allergic skin and/or respiratory reactions in certain sensitive individuals.

**Toxicokinetics/Metabolism:** No data available.

**Target Organ Effects:** Due to lack of data, the classification is not possible.

**Reproductive Effects:** Due to lack of data, the classification is not possible.

Page 6 of 8 Rev. 00/2023



# **Erythromycin Ophthalmic Ointment, 0.5%**

Carcinogenicity: No data available.

National Toxicology Program (NTP): Not considered to be a carcinogen.

International Agency for Research on

Cancer (IARC):

Not considered to be a carcinogen.

Occupational Safety and Health

Administration (OSHA):

Not considered to be a carcinogen.

**Mutagenicity:** Due to lack of data, the classification is not possible.

**Aspiration Hazard:** Based on available data, the classification criteria are

not met.

#### Section 12 - ECOLOGICAL INFORMATION

#### **Ecotoxicity**

Aquatic: Terrestrial:No data available.Persistence andNo data available.Degradability:No data available.Bioaccumulative Potential:No data available.Mobility in Soil:No data available.Other Adverse Effects:OtherAdverse Effects:No data available.

#### Section 13 – DISPOSAL CONSIDERATIONS

Dispose of all waste in accordance with Federal, State and Local regulations.

### **Section 14 – TRANSPORT INFORMATION**

### **Transport Information**

UN Number:

UN Proper Shipping Name:

Transport Hazard Class(es):

Packing Group:

Not applicable.

Not applicable.

Not applicable.

**Department of Transportation:** Not regulated as a hazardous material.

**International Air Transport** 

Association (IATA):

Not regulated as a dangerous good.

**International Maritime Dangerous** 

Good (IMDG):

Not regulated as a dangerous good.

Page 7 of 8 Rev. 00/2023



# **Erythromycin Ophthalmic Ointment, 0.5%**

#### **Section 15 – REGULATORY INFORMATION**

#### **US Federal Regulations:**

**Toxic Substance Control Act** 

(TSCA): This product is a drug regulated by the Food and Drug

Administration (FDA), and is not regulated by TSCA.

**CERCLA Hazardous Substance** 

and Reportable Quantity: Not listed.

SARA 313: Not listed. SARA 302: Not listed.

**State Regulations** 

New Jersey: Erythromycin: Listed. Pennsylvania: Erythromycin: Listed.

California Proposition 65: Not listed.

#### Section 16 – OTHER INFORMATION

Not made with natural rubber latex.

The information given herein is in good faith and to the best of our knowledge, but no warranty expressed or implied is made.

**Revision Date:** 11/16/2023

**Revision Number:** 0

Disclaimer: This document is generated to distribute health, safety and environmental data. It is not a specification sheet and none of the displayed data should be construed as a specification. Information on this SDS sheet was obtained from sources which we believe are reliable, and we believe that the information is complete and accurate. However, the information is provided without any warranty, express or implied, regarding its correctness. Some of the information presented and conclusions drawn are from sources other than direct test data of the substance. The conditions or methods of handling, storage, use and disposal of the product are beyond our control and may also be beyond our knowledge. It is the user's responsibility to determine the suitability of any material for a specific purpose and to adopt such safety precautions as may be necessary. If the product is used as a component in another product, this SDS information may not be applicable. For these reasons, we do not assume any responsibility and expressly disclaim liability for any loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of this product.

Page 8 of 8 Rev. 00/2023